Multiparametric MR Imaging in Abdominal Malignancies

Magnetic Resonance Imaging Clinics of North America

Volumn 24, Issue 1, 2016, Pages 157-186

  Luna, Antonio ^a,b   Pahwa, Shivani ^b   Bonini, Claudio ^c   Alcalá Mata, Lidia ^a   Wright, Katherine L ^b   Gulani, Vikas ^d,e  

^a Health Time ^*  (Spain)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Oroño Medical Diagnostic Center   (Argentina)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

1H MR spectroscopy; Biomarker; DWI; Hepatobiliary contrast agents; MR elastography; MR imaging; Multiparametric; Perfusion MR imaging

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADOLINIUM; GADOXETIC ACID; SORAFENIB; YTTRIUM 90; TUMOR MARKER;

ABDOMINAL CANCER; ARTERIAL SPIN LABELING; BILE DUCT CARCINOMA; CHEMOEMBOLIZATION; CLINICAL TRIAL (TOPIC); CONTRAST ENHANCEMENT; DATA ANALYSIS; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; ELASTOGRAPHY; GALLBLADDER CARCINOMA; HUMAN; IMAGE PROCESSING; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; LIVER PERFUSION; MAGNETIC RESONANCE ELASTOGRAPHY; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERFUSION WEIGHTED IMAGING; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SPIN LABELING; TREATMENT RESPONSE; ABDOMINAL NEOPLASMS; MAGNETIC RESONANCE ANGIOGRAPHY; METABOLISM; MOLECULAR IMAGING; MULTIMODAL IMAGING; NEOPLASMS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES; TRENDS;

ABDOMINAL NEOPLASMS; BIOMARKERS, TUMOR; DIFFUSION MAGNETIC RESONANCE IMAGING; ELASTICITY IMAGING TECHNIQUES; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR IMAGING; MULTIMODAL IMAGING; NEOPLASMS;

EID: 84955165400     PISSN: 10649689     EISSN: 15579786     Source Type: Journal    
DOI: 10.1016/j.mric.2015.08.005     Document Type: Review

References (120)

1. Bartolozzi C., Lencioni R., Donati F., et al. liver and pancreas. Eur Radiol 1999, 9(8):1496-1551.
2. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247.
3. Wahl R.L., Jacene H., Kasamon Y., et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(Suppl 1):122-150.
4. Padhani A.R., Liu G., Koh D.M., et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009, 11(2):102-125.
5. Goh V., Gourtsoyianni S., Koh D.M. Functional imaging of the liver. Semin Ultrasound CT MR 2013, 34(1):54-65.
6. Venkatesh S.K., Yin M., Glockner J.F., et al. MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol 2008, 190(6):1534-1540.
7. Lebedis C., Luna A., Soto J.A. Use of magnetic resonance imaging contrast agents in the liver and biliary tract. Magn Reson Imaging Clin N Am 2012, 20(4):715-737.
8. Luciani A., Vignaud A., Cavet M., et al. Liver cirrhosis: intravoxel incoherent motion MR imaging-pilot study. Radiology 2008, 249(3):891-899.
9. Broncano J., Alcalá A.L., González J., et al. Functional MR Imaging in Chest Malignancies. Magn Reson Imaging Clin N Am 2016, in press.
10. Yoon J.H., Lee J.M., Yu M.H., et al. Evaluation of hepatic focal lesions using diffusion-weighted MR imaging: comparison of apparent diffusion coefficient and intravoxel incoherent motion-derived parameters. J Magn Reson Imaging 2014, 39(2):276-285.
11. Kang K.M., Lee J.M., Yoon J.H., et al. Intravoxel incoherent motion diffusion-weighted MR imaging for characterization of focal pancreatic lesions. Radiology 2014, 270(2):444-453.
12. Rosenkzrantz A.B., Padhani A.R., Chevenert T.L., et al. Body diffusion kurtosis imaging: Basic principles, applications, and considerations for clinical practice. J Magn Reson Imaging 2015.
13. Penner A.H., Sprinkart A.M., Kukuk G.M., et al. Intra-voxel incoherent motion model-based liver lesion characterisation from three b-value diffusion- weighted MRI. Eur Radiol 2013, 23(10):2773-2783.
14. Hardie A.D., Naik M., Hecht E.M., et al. Diagnosis of liver metastases: value of diffusion-weighted MRI compared with gadolinium-enhanced MRI. Eur Radiol 2010, 20(6):1431-1441.
15. Jhaveri K., Cleary S., Audet P., et al. Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid). AJR Am J Roentgenol 2015, 204(3):498-509.
16. Kakite S., Dyvorne H., Besa C., et al. Hepatocellular carcinoma: short-term reproducibility of apparent diffusion coefficient and intravoxel incoherent motion parameters at 3.0T. J Magn Reson Imaging 2015, 41(1):149-156.
17. Bittencourt L.K., Matos C., Coutinho A.C. Diffusion-weighted magnetic resonance imaging in the upper abdomen: technical issues and clinical applications. Magn Reson Imaging Clin N Am 2011, 19(1):111-131.
18. Doblas S., Wagner M., Leitao H.S., et al. Characterizing focal hepatic lesions by free-breathing intravoxel incoherent motion MRI at 3.0 T. Invest Radiol 2013, 48(10):722-728.
19. Faletti R., Cassinis M.C., Fonio P., et al. Multiparametric Gd-EOB-DTPA magnetic resonance in diagnosis of HCC: dynamic study, hepatobiliary phase, and diffusion-weighted imaging compared to histology after orthotopic liver transplantation. Abdom Imaging 2015, 40(1):46-55.
20. Hwang J., Kim Y.K., Kim J.M., et al. Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transpl 2014, 20(12):1436-1446.
21. Chen J., Wu M., Liu R., et al. Preoperative evaluation of the histological grade of hepatocellular carcinoma with diffusion-weighted imaging: a meta-analysis. PLoS One 2015, 10(2):e0117661.
22. Nishie A., Tajima T., Asayama Y., et al. Diagnostic performance of apparent diffusion coefficient for predicting histological grade of hepatocellular carcinoma. Eur J Radiol 2011, 80(2):29-33.
23. Woo S., Lee J.M., Yoon J.H., et al. Intravoxel incoherent motion diffusion-weighted MR imaging of hepatocellular carcinoma: correlation with enhancement degree and histologic grade. Radiology 2014, 270(3):758-767.
24. Motosugi U., Ichikawa T., Sou H., et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 2010, 256(1):151-158.
25. deSouza D.A., Parente D.B., de Araújo A.L., et al. Modern imaging evaluation of the liver: emerging MR imaging techniques and indications. Magn Reson Imaging Clin N Am 2013, 21(2):337-363.
26. Chung J.C., Naik N.K., Lewandowski R.J., et al. Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. World J Gastroenterol 2010, 16(25):3161-3167.
27. Mannelli L., Kim S., Hadju C.H., et al. Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: prediction and assessment of response to transarterial chemoembolization. Preliminary experience. Eur J Radiol 2013, 82(4):577-582.
28. Park Y.S., Lee C.H., Kim J.H., et al. Using intravoxel incoherent motion (IVIM) MR imaging to predict lipiodol uptake in patients with hepatocellular carcinoma following transcatheter arterial chemoembolization: a preliminary result. Magn Reson Imaging 2014, 32(6):638-646.
29. Schraml C., Schwenzer N.F., Martirosian P., et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 2009, 193(4):W301-W307.
30. Lewin M., Fartoux L., Vignaud A., et al. The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. Eur Radiol 2011, 21(2):281-290.
31. Koh D.M., Scurr E., Collins D., et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 2007, 188(4):1001-1008.
32. Barabasch A., Kraemer N.A., Ciritsis A., et al. Diagnostic accuracy of diffusion-weighted magnetic resonance imaging versus positron emission tomography/computed tomography for early response assessment of liver metastases to y90-radioembolization. Invest Radiol 2015, 50(6):409-415.
33. Mungai F., Pasquinelli F., Mazzoni L.N., et al. Diffusion-weighted magnetic resonance imaging in the prediction and assessment of chemotherapy outcome in liver metastases. Radiol Med 2014, 119(8):625-633.
34. Heijmen L., ter Voert E.E., Oyen W.J., et al. Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer. PLoS One 2015, 10(4):e0120823.
35. Cui X.Y., Chen H.W., Cai S., et al. Diffusion-weighted MR imaging for detection of extrahepatic cholangiocarcinoma. Eur J Radiol 2012, 81(11):2961-2965.
36. Park H.J., Kim Y.K., Park M.J., et al. Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 2013, 38(4):793-801.
37. Kim S.J., Lee J.M., Kim H., et al. Role of diffusion-weighted magnetic resonance imaging in the diagnosis of gallbladder cancer. J Magn Reson Imaging 2013, 38(1):127-137.
38. Wu L.M., Hu J.N., Hua J., et al. Diagnostic value of diffusion-weighted magnetic resonance imaging compared with fluorodeoxyglucose positron emission tomography/computed tomography for pancreatic malignancy: a meta-analysis using a hierarchical regression model. J Gastroenterol Hepatol 2012, 27(6):1027-1035.
39. Muraoka N., Uematsu H., Kimura H., et al. Apparent diffusion coefficient in pancreatic cancer: characterization and histopathological correlations. J Magn Reson Imaging 2008, 27(6):1302-1308.
40. Fukukura Y., Takumi K., Kamimura K., et al. Pancreatic adenocarcinoma: variability of diffusion-weighted MR imaging findings. Radiology 2012, 263(3):732-740.
41. Rosenkrantz A.B., Matza B.W., Sabach A., et al. Pancreatic cancer: lack of association between apparent diffusion coefficient values and adverse pathological features. Clin Radiol 2013, 68(4):e191-e197.
42. Wang Y., Chen Z.E., Nikolaidis P., et al. Diffusion-weighted magnetic resonance imaging of pancreatic adenocarcinomas: association with histopathology and tumor grade. J Magn Reson Imaging 2011, 33(1):136-142.
43. Lemke A., Laun F.B., Klauss M., et al. Differentiation of pancreas carcinoma from healthy pancreatic tissue using multiple b-values: comparison of apparent diffusion coefficient and intravoxel incoherent motion derived parameters. Invest Radiol 2009, 44(12):769-777.
44. Cuneo K.C., Chenevert T.L., Ben-Josef E., et al. A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol 2014, 7(5):644-649.
45. Muhi A., Ichikawa T., Motosugi U., et al. Mass-forming autoimmune pancreatitis and pancreatic carcinoma: differential diagnosis on the basis of computed tomography and magnetic resonance cholangiopancreatography, and diffusion-weighted imaging findings. J Magn Reson Imaging 2012, 35(4):827-836.
46. Wang Y., Chen Z.E., Yaghmai V., et al. Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics. J Magn Reson Imaging 2011, 33(5):1071-1079.
47. 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. Eur J Nucl Med Mol Imaging 2013, 40(6):897-907.
48. Wang Y., Miller F.H., Chen Z.E., et al. Diffusion-weighted MR imaging of solid and cystic lesions of the pancreas. Radiographics 2011, 31(3):47-64.
49. Karatzas T., Dimitroulis D., Charalampoudos P., et al. Management of cystic and solid pancreatic incidentalomas: a review analysis. J BUON 2013, 18(1):17-24.
50. Boraschi P., Donati F., Gigoni R., et al. Diffusion-weighted MRI in the characterization of cystic pancreatic lesions: usefulness of ADC values. Magn Reson Imaging 2010, 28(10):1447-1455.
51. Fatima Z., Ichikawa T., Motosugi U., et al. Magnetic resonance diffusion-weighted imaging in the characterization of pancreatic mucinous cystic lesions. Clin Radiol 2011, 66(2):108-111.
52. Chen B.-B., Hsu C.-Y., Yu C.-W., et al. Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. Eur Radiol 2012, 22(1):171-180.
53. Annet L., Materne R., Danse E., et al. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 2003, 229(2):409-414.
54. Abdullah S.S., Pialat J.B., Wiart M., et al. Characterization of hepatocellular carcinoma and colorectal liver metastasis by means of perfusion MRI. J Magn Reson Imaging 2008, 28(2):390-395.
55. Hsu C.-Y., Shen Y.-C., Yu C.-W., et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol 2011, 55(4):858-865.
56. Yopp A.C., Schwartz L.H., Kemeny N., et al. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol 2011, 18(8):2192-2199.
57. Zhu A.X., Sahani D.V., Duda D.G., et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009, 27:3027-3035.
58. Jarnagin W.R., Schwartz L.H., Gultekin D.H., et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 2009, 20(9):1589-1595.
59. Wang J., Chen L.T., Tsang Y.M., et al. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR Am J Roentgenol 2004, 183:713-719.
60. Akisik M.F., Sandrasegaran K., Bu G., et al. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. Radiology 2010, 256(2):441-449.
61. Scharf J., Zapletal C., Hess T., et al. Assessment of hepatic perfusion in pigs by pharmacokinetic analysis of dynamic MR images. J Magn Reson Imaging 1999, 9:568-572.
62. Sourbron S., Sommer W.H., Reiser M.F., et al. Combined quantification of liver perfusion and function with dynamic gadoxetic acid-enhanced MR imaging. Radiology 2012, 263:874-883.
63. Koh T.S., Thng C.H., Lee P.S., et al. Hepatic metastases: in vivo assessment of perfusion parameters at dynamic contrast-enhanced MR imaging with dual-input two-compartment tracer kinetics model. Radiology 2008, 249:307-320.
64. Wang H.Z., Riederer S.J., Lee J.N. Optimizing the precision in T1 relaxation estimation using limited flip angles. Magn Reson Med 1987, 5:399-416.
65. Sourbron S. Technical aspects of MR perfusion. Eur J Radiol 2010, 76:304-313.
66. Judd R.M., Reeder S.B., Atalar E., et al. A magnetization-driven gradient echo pulse sequence for the study of myocardial perfusion. Magn Reson Med 1995, 34:276-282.
67. Goh V., Liaw J., Bartram C.I., et al. Effect of temporal interval between scan acquisitions on quantitative vascular parameters in colorectal cancer: implications for helical volumetric perfusion CT techniques. AJR Am J Roentgenol 2008, 191(6):W288-W292.
68. Margosian P., Schmitt F. Faster MR imaging: imaging with half the data. Heal Care Instrum 1986, 1:195-197.
69. Jones R.A., Haraldseth O., Müller T.B., et al. K-space substitution: a novel dynamic imaging technique. Magn Reson Med 1993, 29:830-834.
70. Song T., Laine A.F., Chen Q., et al. Optimal k-space sampling for dynamic contrast-enhanced MRI with an application to MR renography. Magn Reson Med 2009, 61:1242-1248.
71. Griswold M.A., Jakob P.M., Heidemann R.M., et al. Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med 2002, 47:1202-1210.
72. Pruessmann K.P., Weiger M., Scheidegger M.B., et al. SENSE: sensitivity encoding for fast MRI. Magn Reson Med 1999, 42:952-962.
73. Rao S.-X., Chen C.-Z., Liu H., et al. Three-dimensional whole-liver perfusion magnetic resonance imaging in patients with hepatocellular carcinomas and colorectal hepatic metastases. BMC Gastroenterol 2013, 13:53.
74. Thng C.H., Koh T.S., Collins D.J., et al. Perfusion magnetic resonance imaging of the liver. World J Gastroenterol 2010, 16:1598-1609.
75. Chandarana H., Taouli B. Diffusion and perfusion imaging of the liver. Eur J Radiol 2010, 76:348-358.
76. Bultman E.M., Brodsky E.K., Horng D.E., et al. Quantitative hepatic perfusion modeling using DCE-MRI with sequential breathholds. J Magn Reson Imaging 2014, 39:853-865.
77. Salmani Rahimi M., Korosec F.R., Wang K., et al. Combined dynamic contrast-enhanced liver MRI and MRA using interleaved variable density sampling. Magn Reson Med 2015, 73(3):973-983.
78. Feng L., Grimm R., Block K.T., et al. Golden-angle radial sparse parallel MRI: combination of compressed sensing, parallel imaging, and golden-angle radial sampling for fast and flexible dynamic volumetric MRI. Magn Reson Med 2014, 72(3):707-717.
79. Hagiwara M., Rusinek H., Lee V.S., et al. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging-initial experience. Radiology 2008, 246:926-934.
80. Miyazaki K., Orton M.R., Davidson R.L., et al. Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response. Radiology 2012, 263:139-148.
81. Michaely H.J., Sourbron S.P., Buettner C., et al. Temporal constraints in renal perfusion imaging with a 2-compartment model. Invest Radiol 2008, 43:120-128.
82. Materne R., Smith A.M., Peeters F., et al. Assessment of hepatic perfusion parameters with dynamic MRI. Magn Reson Med 2002, 47:135-142.
83. Chandarana H., Feng L., Block T.K., et al. Free-breathing contrast-enhanced multiphase MRI of the liver using a combination of compressed sensing, parallel imaging, and golden-angle radial sampling. Invest Radiol 2013, 48(1):10-16.
84. Mendichovszky I.A., Cutajar M., Gordon I. Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study. Eur J Radiol 2009, 71(3):576-581.
85. Chen Y., Lee G.R., Wright K.L., et al. Free-breathing liver perfusion imaging using 3-dimensional through-time spiral generalized autocalibrating partially parallel acquisition acceleration. Invest Radiol 2015, 50(6):367-375.
86. Michoux N., Montet X., Pechère A., et al. Parametric and quantitative analysis of MR renographic curves for assessing the functional behaviour of the kidney. Eur J Radiol 2005, 54(1):124-135.
87. Brodsky E.K., Bultman E.M., Johnson K.M., et al. High-spatial and high-temporal resolution dynamic contrast-enhanced perfusion imaging of the liver with time-resolved three-dimensional radial MRI. Magn Reson Med 2014, 71(3):934-941.
88. Ho V.B., Allen S.F., Hood M.N., et al. Renal masses: quantitative assessment of enhancement with dynamic MR imaging. Radiology 2002, 224(3):695-700.
89. Scharf J., Kemmling A., Hess T., et al. Assessment of hepatic perfusion in transplanted livers by pharmacokinetic analysis of dynamic magnetic resonance measurements. Invest Radiol 2007, 42(4):224-229.
90. Brix G., Lucht R., Griebel J. Tracer kinetic analysis of signal time series from dynamic contrast-enhanced MR imaging. Biomed Tech (Berl) 2006, 51(5-6):325-330.
91. Chen B.-B., Shih T.T.-F. DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker. World J Gastroenterol 2014, 20(12):3125-3134.
92. Sourbron S.P., Buckley D.L. Tracer kinetic modelling in MRI: estimating perfusion and capillary permeability. Phys Med Biol 2011, 57(2):R1-R33.
93. Tofts P.S., Brix G., Buckley D.L., et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, 10(3):223-232.
94. Totman J.J., O'Gorman R.L., Kane P.A., et al. Comparison of the hepatic perfusion index measured with gadolinium-enhanced volumetric MRI in controls and in patients with colorectal cancer. Br J Radiol 2005, 78(926):105-109.
95. Tsushima Y., Blomley M.J.K., Yokoyama H., et al. Does the presence of distant and local malignancy alter parenchymal perfusion in apparently disease-free areas of the liver?. Dig Dis Sci 2001, 46(10):2113-2119.
96. Hirashima Y., Yamada Y., Tateishi U., et al. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer 2012, 130(10):2359-2365.
97. Liang P.-C., Ch'ang H.-J., Hsu C., et al. Dynamic MRI signals in the second week of radiotherapy relate to treatment outcomes of hepatocellular carcinoma: a preliminary result. Liver Int 2007, 27(4):516-528.
98. Murphy P., Koh D.-M. Imaging in clinical trials. Cancer Imaging 2010, 10 Spec no:S74-S82.
99. Song H.K., Dougherty L. Dynamic MRI with projection reconstruction and KWIC processing for simultaneous high spatial and temporal resolution. Magn Reson Med 2004, 52(4):815-824.
100. Kim J.H., Lee J.M., Park J.H., et al. Solid pancreatic lesions: characterization by using timing bolus dynamic contrast-enhanced MR imaging assessment-a preliminary study. Radiology 2013, 266(1):185-196.
101. Konstantinidis I.T., Do R.K.G., Gultekin D.H., et al. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol 2014, 21(8):2675-2683.
102. Sánchez-González J., Luna A., da Cruz L.C. Perfusion imaging by magnetic resonance. Functional imaging in oncology: biophysical basis and technical approaches 2014, vol. 1:341-376. Springer, Berlin.
103. Cai W., Li F., Wang J., et al. A comparison of arterial spin labeling perfusion MRI and DCE-MRI in human prostate cancer. NMR Biomed 2014, 27(7):817-825.
104. Bazelaire C De, Rofsky N.M., Duhamel G., et al. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). Acad Radiol 2005, 12(3):347-357.
105. Aguirre-Reyes D.F., Sotelo J.A., Arab J.P., et al. Intrahepatic portal vein blood volume estimated by non-contrast magnetic resonance imaging for the assessment of portal hypertension. Magn Reson Imaging 2015, 33(8):970-977.
106. Schraml C., Schwenzer N.F., Martirosian P., et al. Perfusion imaging of the pancreas using an arterial spin labeling technique. J Magn Reson Imaging 2008, 28(6):1459-1465.
107. Luna A., Martin T., Alcala-Mata L., et al. Feasibility of arterial spin label to differentiate solid and cystic focal liver lesions 2014, Scientific poster gastrointestinal (MR technique), RSNA, SSQ08-2.
108. ter Voert E.G., Heijmen L., van Laarhoven H.W., et al. In vivo magnetic resonance spectroscopy of liver tumors and metastases. World J Gastroenterol 2011, 17(47):5133-5149.
109. Kuo Y.T., Li C.W., Chen C.Y., et al. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging 2004, 19(5):598-604.
110. Soper R., Himmelreich U., Painter D., et al. Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance spectroscopy and a statistical classification strategy. Pathology 2002, 34(5):417-422.
111. Fischbach F., Schirmer T., Thormann M., et al. Quantitative proton magnetic resonance spectroscopy of the normal liver and malignant hepatic lesions at 3.0 Tesla. Eur Radiol 2008, 18(11):2549-2558.
112. Xu L., Liu B., Huang Y., et al. 3.0 T proton magnetic resonance spectroscopy of the liver: quantification of choline. World J Gastroenterol 2013, 19(9):1472-1477.
113. Van Beers B.E., Daire J.L., Garteiser P. New imaging techniques for liver diseases. J Hepatol 2015, 62(3):690-700.
114. Chen L., Zhang J., Zhang L., et al. Meta-analysis of gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging for the detection of liver metastases. PLoS One 2012, 7(11):e48681.
115. Park Y., Kim S.H., Kim S.H., et al. Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience. Korean J Radiol 2010, 11(4):433-440.
116. Marin D., Di Martino M., Guerrisi A., et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology 2009, 251(1):85-95.
117. Grazioli L., Morana G., Kirchin M.A., et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005, 236(1):166-177.
118. Grazioli L., Bondioni M.P., Haradome H., et al. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 2012, 262(2):520-529.
119. Soulez G., Bloomgarden D.C., Rofsky N.M., et al. Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3-5 chronic kidney disease undergoing MRI with injected gadobenate dimeglumine or gadoteridol. AJR Am J Roentgenol 2015, 205(3):469-478.
120. Nandwana S.B., Moreno C.C., Osipow M.T., et al. Gadobenate dimeglumine administration and nephrogenic systemic fibrosis: Is there a real risk in patients with impaired renal function?. Radiology 2015, 276(3):741-747.